Microenvironmental alterations Mycobacterium leprae: a systematized review
DOI:
https://doi.org/10.5281/zenodo.20634910Palavras-chave:
Leprosy, Mycobacterium leprae, microenvironment, lysosomes, innate immunityResumo
Leprosy is a chronic infectious disease caused by Mycobacterium leprae, an obligate intracellular pathogen with tropism for macrophages and Schwann cells, predominantly affecting the skin and peripheral nerves. Despite the effectiveness of multidrug therapy (MDT) recommended by the World Health Organization (WHO), limitations such as emerging drug resistance, adverse effects, long therapeutic duration, and persistence of neurological sequelae stimulate the search for new therapeutic approaches. This systematic review analyzed the role of the leprosy microenvironment. In vitro and in vivo studies, molecular analyses, and systematic reviews involving mechanisms were included. The study highlights the relevance of lysosomes and their dynamics of the cellular microenvironment in bacillary persistence and the immune response to leprosy. In this context, strategies integrating pathophysiology and immunomodulation emerge as promising perspectives for the development of new anti-leprosy agents.
Referências
ARBEIT, R. D. et al. Genetic diversity among strains of Mycobacterium tuberculosis. Journal of Infectious Diseases, v. 168, n. 3, p. 622-628, 1993. DOI: https://doi.org/10.1093/infdis/168.3.622.
BALLABIO, A.; BONIFACINO, J. S. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nature Reviews Molecular Cell Biology, v. 21, n. 2, p. 101-118, 2020. DOI: https://doi.org/10.1038/s41580-019-0185-4.
BANERJEE, A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science, v. 263, n. 5144, p. 227-230, 1994. DOI: https://doi.org/10.1126/science.8284673.
BERLINCK, R. G. S. et al. Challenges and rewards of research in marine natural products chemistry in Brazil. Natural Product Reports, v. 34, n. 9, p. 1007-1024, 2017. DOI: https://doi.org/10.1039/C7NP00025A.
BHATT, K. et al. Exploitation of natural products as an alternative to conventional drug discovery approaches for the treatment of tuberculosis. Drug Resistance Updates, v. 12, n. 4-5, p. 99-108, 2009. DOI: https://doi.org/10.1016/j.drup.2009.06.002.
BRASIL. Ministério da Saúde. Boletim epidemiológico: hanseníase. Brasília, DF: Ministério da Saúde, 2023.
BRASIL. Ministério da Saúde. Dermatologia na atenção básica à saúde. 2. ed. Brasília, DF: Ministério da Saúde, 2002.
BRASIL. Ministério da Saúde. Diretrizes para vigilância, atenção e eliminação da hanseníase como problema de saúde pública. Brasília, DF: Ministério da Saúde, 2023.
BRASIL. Ministério da Saúde. Guia de vigilância em saúde. 4. ed. Brasília, DF: Ministério da Saúde, 2022.
BRASIL. Ministério da Saúde. Guia prático sobre hanseníase. Brasília, DF: Ministério da Saúde, 2017.
BRASIL. Ministério da Saúde. Manual de prevenção de incapacidades em hanseníase. 3. ed. Brasília, DF: Ministério da Saúde, 2008.
BRENNAN, P. J.; NIKAIDO, H. The envelope of mycobacteria. Annual Review of Biochemistry, v. 64, p. 29-63, 1995. DOI: https://doi.org/10.1146/annurev.bi.64.070195.000333.
BURT, S. Essential oils: their antibacterial properties and potential applications in foods. International Journal of Food Microbiology, v. 94, n. 3, p. 223-253, 2004. DOI: https://doi.org/10.1016/j.ijfoodmicro.2004.03.022.
CAMBAU, E. et al. Antimicrobial susceptibility testing in leprosy. Clinical Microbiology Reviews, v. 31, n. 4, e00022-18, 2018. DOI: https://doi.org/10.1128/CMR.00022-18.
CHENG, C. et al. Antimycobacterial activities of catechins. Scientific Reports, v. 9, p. 18001, 2019. DOI: https://doi.org/10.1038/s41598-019-54397-9.
COELHO, C. A. et al. Propolis components inhibit multidrug-resistant Mycobacterium tuberculosis. Letters in Applied Microbiology, v. 70, n. 4, p. 313-319, 2020. DOI: https://doi.org/10.1111/lam.13289.
COLE, S. T. et al. Massive gene decay in the leprosy bacillus. Nature, v. 409, p. 1007-1011, 2001. DOI: https://doi.org/10.1038/35059006.
CRAGG, G. M.; NEWMAN, D. J. Natural products as sources of new drugs. Biochimica et Biophysica Acta, v. 1830, p. 3670-3695, 2013. DOI: https://doi.org/10.1016/j.bbagen.2013.02.008.
DEPS, P. et al. Challenges in the treatment of leprosy reactions. Transactions of the Royal Society of Tropical Medicine and Hygiene, v. 114, n. 2, p. 73-82, 2020. DOI: https://doi.org/10.1093/trstmh/trz118.
DERETIC, V.; SAITO, S.; SAITO, N. Autophagy in infection and immunity: lessons from mycobacteria. Cell Host & Microbe, v. 13, n. 6, p. 650-660, 2013. DOI: https://doi.org/10.1016/j.chom.2013.05.009.
DUMAS DOS SANTOS, F. S.; ALVES DE SOUZA, L. P.; SIANI, A. C. Chaulmoogra oil as scientific knowledge: the construction of an antileprotic therapy. História, Ciências, Saúde – Manguinhos, v. 15, n. 1, 2008. DOI: https://doi.org/10.1590/S0104-59702008000100003.
EDMOND, C.; ROLLET, M. The treatment of leprosy with gynocardia oil. Indian Medical Gazette, v. 44, p. 381-387, 1909.
EIDT, L. M. Having leprosy: a journey of feelings and experiences. Rio de Janeiro: Sociedade Brasileira de Dermatologia, 2015.
FISCHER, M. et al. Mycobacterium leprae: an ancient pathogen with modern challenges. Current Opinion in Infectious Diseases, v. 35, n. 4, p. 234-240, 2022. DOI: https://doi.org/10.1097/QCO.0000000000000832.
FRANZBLAU, S. G. et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates using the Alamar Blue microplate assay. Journal of Clinical Microbiology, v. 36, n. 2, p. 362-366, 1998. DOI: https://doi.org/10.1128/JCM.36.2.362-366.1998.
GOULART, I. M. B.; PENNA, G. O.; CUNHA, G. Immunopathology of leprosy: complexity of host immune response. Revista da Sociedade Brasileira de Medicina Tropical, v. 35, n. 4, p. 365-375, 2002. DOI: https://doi.org/10.1590/S0037-86822002000400013.
GUTIERREZ, M. G. et al. Autophagy is a defense mechanism inhibiting Mycobacterium tuberculosis survival. Cell, v. 119, n. 6, p. 753-766, 2004. DOI: https://doi.org/10.1016/j.cell.2004.11.038.
HUANG, Z. B. et al. Mechanisms of resistance to quinolone antibacterial agents. Molecules, v. 19, n. 1, p. 1089-1105, 2014. DOI: https://doi.org/10.3390/molecules19011089.
JACOBS, W. R. Jr. et al. Development of luciferase reporter mycobacteriophages. In: HATFULL, G. F.; JACOBS, W. R. Jr. (ed.). Molecular genetics of mycobacteria. Washington, DC: ASM Press, 2016. p. 477-492.
JACOBS, W. R. Jr. et al. Rapid drug susceptibility testing of Mycobacterium tuberculosis. Science, v. 260, n. 5109, p. 819-822, 1993.
JACOBSON, R. R.; KRAHENBUHL, J. L. Leprosy. The Lancet, v. 353, n. 9153, p. 655-660, 1999. DOI: https://doi.org/10.1016/S0140-6736(98)06322-3.
KALLURI, R.; ZEISBERG, M. Fibroblasts in cancer. Nature Reviews Cancer, v. 6, n. 5, p. 392-401, 2006. DOI: https://doi.org/10.1038/nrc1877.
KAPLAN, G. et al. Pathogenesis of nerve damage in leprosy. Trends in Microbiology, v. 27, n. 9, p. 742-754, 2019. DOI: https://doi.org/10.1016/j.tim.2019.04.008.
KIRCHHEIMER, W. F.; STORRS, E. E. Attempts to establish the armadillo as a model for leprosy. International Journal of Leprosy, v. 39, n. 3, p. 693-702, 1971.
KUMAR, R. A. et al. Anti-leprosy activity of Indian medicinal plants. Journal of Ethnopharmacology, v. 142, n. 2, p. 458-465, 2012. DOI: https://doi.org/10.1016/j.jep.2012.05.012.
LAMBERT, R. J. et al. Mode of action of oregano oil and carvacrol. Journal of Applied Microbiology, v. 91, n. 3, p. 453-462, 2001. DOI: https://doi.org/10.1046/j.1365-2672.2001.01428.x.
LASTÓRIA, J. C.; ABREU, M. A. M. M. Hanseníase: diagnóstico e tratamento. Diagnosis & Treatment, v. 19, n. 4, p. 179-185, 2014.
LAVANIA, M. et al. Drug resistance mutations in Mycobacterium leprae. Infection, Genetics and Evolution, v. 30, p. 6-11, 2015. DOI: https://doi.org/10.1016/j.meegid.2014.11.026.
LOCKWOOD, D. N. J.; SATYANARAYANA, S. Leprosy. The Lancet, v. 364, n. 9430, p. 233-239, 2004. DOI: https://doi.org/10.1016/S0140-6736(04)16680-5.
LOUGHEED, K. E. A. et al. New anti-tuberculosis agents. Tuberculosis, v. 89, n. 5, p. 364-370, 2009. DOI: https://doi.org/10.1016/j.tube.2009.07.006.
MASAKI, T. et al. Reprogramming of Schwann cells by Mycobacterium leprae. Cell, v. 154, n. 1, p. 51-62, 2013. DOI: https://doi.org/10.1016/j.cell.2013.06.011.
MAYER-BARBER, K. D. et al. Interferons in tuberculosis infection. Immunity, v. 35, n. 6, p. 1023-1034, 2011.
MDLULI, K.; SPIGELMAN, M. TB drug discovery targets. Current Opinion in Pharmacology, v. 6, n. 5, p. 459-467, 2006. DOI: https://doi.org/10.1016/j.coph.2006.06.004.
MINUZZO, D. A. The leprosy patient. Évora: Universidade de Évora, 2008.
MINUZZO, F. M. A. Hanseníase: representações sociais de estudantes de medicina. Petrópolis: Faculdade de Medicina de Petrópolis, 2001.
MODLIN, R. L. Innate immune response in leprosy. Current Opinion in Immunology, v. 22, n. 1, p. 48-54, 2010. DOI: https://doi.org/10.1016/j.coi.2009.12.004.
MODLIN, R. L. et al. Lymphokine production in leprosy. Journal of Immunology, v. 136, n. 6, p. 2279-2283, 1986.
MONOT, M. et al. Genomic analysis of Mycobacterium leprae. Nature Genetics, v. 41, n. 12, p. 1282-1289, 2009. DOI: https://doi.org/10.1038/ng.477.
NANDAKUMAR, M. et al. Rifampicin, isoniazid, ethambutol and pyrazinamide. In: KUMAR, M. (ed.). Tuberculosis chemotherapy. London: Springer, 2010. p. 15-53.
NEWMAN, D. J.; CRAGG, G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, v. 83, n. 3, p. 770-803, 2020. DOI: https://doi.org/10.1021/acs.jnatprod.9b01285.
ORTEGA-OJEDA, F. E. et al. Molecular docking of potential antimycobacterial natural compounds against Mycobacterium leprae targets. Journal of Molecular Modeling, v. 26, n. 4, p. 87, 2020. DOI: https://doi.org/10.1007/s00894-020-04346-1.
PARASCANDOLA, J. From chaulmoogra to promin: treatment of leprosy reaches the modern era. Pharmacy in History, v. 45, n. 1, p. 3-14, 2003.
PENNA, G. O. et al. Leprosy among Amerindians of Brazil: prevalence and spatial distribution in indigenous and non-indigenous population. PLoS Neglected Tropical Diseases, v. 14, n. 10, e0008796, 2020. DOI: https://doi.org/10.1371/journal.pntd.0008796.
RAMASWAMY, S. et al. Lipid metabolism and foam cell formation in lepromatous leprosy: implications for disease pathogenesis. Frontiers in Immunology, v. 12, p. 745621, 2021. DOI: https://doi.org/10.3389/fimmu.2021.745621.
RASTOGI, N. et al. In vitro activities of fourteen antimycobacterial drugs against drug-susceptible and drug-resistant clinical isolates of the Mycobacterium tuberculosis complex. Antimicrobial Agents and Chemotherapy, v. 36, n. 10, p. 2349-2352, 1992. DOI: https://doi.org/10.1128/AAC.36.10.2349.
RATES, S. M. K. Plants as source of drugs. Toxicon, v. 39, n. 5, p. 603-613, 2001. DOI: https://doi.org/10.1016/S0041-0101(00)00154-9.
RIBEIRO, M. C. et al. In vitro anti-mycobacterial activity and immunomodulatory effects of Brazilian green propolis. Brazilian Journal of Microbiology, v. 51, n. 3, p. 1125-1134, 2020. DOI: https://doi.org/10.1007/s42770-020-00287-9.
RICHARDSON, P. M. et al. Clofazimine in the management of lepromatous leprosy. Leprosy Review, v. 80, n. 3, p. 266-273, 2009. DOI: https://doi.org/10.47276/lr.80.3.266.
RIDLEY, D. S.; JOPLING, W. H. A classification of leprosy for research purposes. Leprosy Review, v. 37, n. 3, p. 97-113, 1966.
RIDLEY, D. S.; JOPLING, W. H. Classification of leprosy according to immunity: a five-group system. International Journal of Leprosy and Other Mycobacterial Diseases, v. 34, n. 3, p. 255-273, 1966.
RODRIGUES, L. C.; LOCKWOOD, D. N. J. Leprosy now: epidemiology, progress, challenges, and research gaps. The Lancet Infectious Diseases, v. 11, n. 6, p. 464-470, 2011. DOI: https://doi.org/10.1016/S1473-3099(11)70006-8.
ROZWARSKI, D. A. et al. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science, v. 279, n. 5347, p. 98-102, 1998. DOI: https://doi.org/10.1126/science.279.5347.98.
SAFTIG, P.; KLUENKAMP, M. Lysosomes: more than a garbage disposal. Nature Reviews Molecular Cell Biology, v. 12, n. 9, p. 563-574, 2011. DOI: https://doi.org/10.1038/nrm3168.
SCHENCK, M. et al. Specialized pro-resolving mediators in leprosy: imbalance and therapeutic potential. Journal of Lipid Research, v. 59, n. 8, p. 1432-1441, 2018. DOI: https://doi.org/10.1194/jlr.M084312.
SFORCIN, J. M.; BANKOVA, V. Propolis: is there a potential for the development of new drugs? Journal of Ethnopharmacology, v. 133, n. 2, p. 253-260, 2011. DOI: https://doi.org/10.1016/j.jep.2010.10.032.
SILVA, A. M. et al. Host lipid metabolism as a target for Mycobacterium leprae persistence. Trends in Parasitology, v. 36, n. 11, p. 890-902, 2020. DOI: https://doi.org/10.1016/j.pt.2020.08.007.
SINGHAL, A. et al. Metformin as adjunct antituberculosis therapy. Science Translational Medicine, v. 6, n. 263, p. 263ra159, 2014. DOI: https://doi.org/10.1126/scitranslmed.3009498.
SINGLA, R. K.; DUBEY, A. K. Natural products as potential anti-leprosy agents. Pharmacognosy Reviews, v. 8, n. 15, p. 45-52, 2014. DOI: https://doi.org/10.4103/0973-7847.125526.
STENGEL, S. T. et al. Autophagy and macrophage polarization in leprosy: clinical and immunological implications. Clinical Microbiology and Infection, v. 21, n. 5, p. 456-463, 2015. DOI: https://doi.org/10.1016/j.cmi.2014.12.015.
ULTEE, A. et al. The phenolic hydroxyl group of carvacrol is essential for action against the food-borne pathogen Bacillus cereus. Applied and Environmental Microbiology, v. 68, n. 4, p. 1561-1568, 2002. DOI: https://doi.org/10.1128/AEM.68.4.1561-1568.2002.
VARRICCHIO, M. C. B. N. et al. Atualização sobre a epidemiologia da hanseníase (micobacteriose). INFO-SAPB, v. 10, n. 1, 2026.
VARRICCHIO, M. C. B. N.; GASPAR, S. A.; DA SILVA, J.; DINÓLA, I. C. S.; DA SILVA, E. P.; DA SILVA, S.; PYRRHO, A. dos S.; KUSTER, R. M. Euphorbia resinifera and traditional medicine. OWL Journal Magazine, v. 4, n. 5, 2026. DOI: https://doi.org/10.5281/zenodo.20371996. Disponível em: https://revistaowl.com.br/index.php/owl/article/view/808. Acesso em: 10 jun. 2026.
VEDITHI, S. C. et al. Drug targets and novel compounds against Mycobacterium leprae. Pathogens and Disease, v. 78, n. 4, ftaa022, 2020. DOI: https://doi.org/10.1093/femspd/ftaa022.
VEDITHI, S. C. et al. Structural implications of mutations in drug resistance in leprosy. Scientific Reports, v. 8, n. 1, p. 3685, 2018. DOI: https://doi.org/10.1038/s41598-018-22096-6.
WORLD HEALTH ORGANIZATION. Enhanced global strategy for further reducing the disease burden due to leprosy. New Delhi: WHO Regional Office for South-East Asia, 2009.
WORLD HEALTH ORGANIZATION. Global leprosy (Hansen disease) strategy 2021–2030: towards zero leprosy. Geneva: World Health Organization, 2021.
WORLD HEALTH ORGANIZATION. Global leprosy (Hansen disease) update 2022: new paradigm – control to elimination. Weekly Epidemiological Record, Geneva, v. 98, n. 36, p. 409-430, 2023.
WORLD HEALTH ORGANIZATION. Global leprosy update 2020: impact of COVID-19 on global leprosy control. Weekly Epidemiological Record, Geneva, v. 96, n. 36, p. 421-444, 2021.
WORLD HEALTH ORGANIZATION. Guidelines for the diagnosis, treatment and prevention of leprosy. Geneva: World Health Organization, 2018.
WORLD HEALTH ORGANIZATION. WHO guidelines for the diagnosis, treatment and prevention of leprosy. Geneva: World Health Organization, 2023. Disponível em: https://www.who.int/publications/i/item/9789240075321. Acesso em: 15 mar. 2026.
WU, M.; JAIN, R. K. The tumor microenvironment at a glance. Cell, v. 183, n. 3, p. 548-550, 2020. DOI: https://doi.org/10.1016/j.cell.2020.10.001.
ZHAO, W. H. et al. Inhibition of coagulase activity in Staphylococcus aureus by combination of epigallocatechin gallate and oxacillin. Journal of Antimicrobial Chemotherapy, v. 48, n. 4, p. 549-555, 2011.
